Or Eisenberg bought $200k of NRSN
Chief Financial Officer at NeuroSense Therapeutics Ltd.. 250,000 shares at an average of $0.80, traded Jun 16, 2026, filed Jun 17, 2026.
Score components
- +22RoleCFO
- +12Trade size$200k at market
- +3Relative to holdingsHoldings up 20%
- +18Price context2% above the 52-week low; 71% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-26-069662, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 16, 2026 | POpen-market purchase Ordinary Shares | +250,000 | $0.80 | $200k | 1,504,050 | Jun 17, 2026 |
Related signals
Other insiders at NeuroSense Therapeutics Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 66Notable | NeuroSense Therapeutics Ltd. | Alon Ben-Noon Chief Executive Officer | $200k 250,000 shares | +6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.